Upgrade to SI Premium - Free Trial

Viridian Therapeutic (VRDN) Reiterated at Market Outperform by Citizens: Lumvoa Approved

June 29, 2026 4:47 AM
Citizens analyst Jason Butler reiterated a Market Outperform rating and $35.00 price target on Viridian Therapeutic (NASDAQ: VRDN).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles